- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- PF-03084014
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 18
- States / cities
- Stanford, California • Chicago, Illinois • New Lenox, Illinois + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 16,128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
- Interventions
- PCR/PCR/LDR Strategy
- Genetic
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 21,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab pegol
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Covina, California • Upland, California + 10 more
- Conditions
- Breast Cancer Stage IIB
- Interventions
- Hydroxychloroquine, Everolimus
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer, Brain Metastases
- Interventions
- Whole Brain Radiotherapy (WBRT), Sorafenib
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Head and Neck Cancers, Breast Cancer, Thoracic Cancers, Liver Cancer, Genito Urinary Cancer, Gastrointestinal Cancers
- Interventions
- Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
- Device
- Lead sponsor
- Varian, a Siemens Healthineers Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Columbus, Ohio
- Conditions
- Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 5 Years to 85 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Not listed
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 13 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer, Breast Cancer Female
- Interventions
- Arm A: Radiotherapy Omission, Arm B: Standard Treatment
- Radiation · Other
- Lead sponsor
- Breast Cancer Trials, Australia and New Zealand
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 2
- States / cities
- San Francisco, California • Houston, Texas
- Conditions
- Rheumatic Diseases
- Interventions
- Cortisol
- Drug
- Lead sponsor
- Helen Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2016
- U.S. locations
- 1
- States / cities
- Apache Junction, Arizona
- Conditions
- HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
- Interventions
- BDC-1001, Nivolumab
- Drug
- Lead sponsor
- Bolt Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 11
- States / cities
- Palo Alto, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Onychomycosis
- Interventions
- Noveon laser
- Device
- Lead sponsor
- Nomir Medical Technologies
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Atopic Dermatitis
- Interventions
- Pimecrolimus, Corticosteroid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 3 Months to 18 Months
- Enrollment
- 1,091 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
- Conditions
- Breast Cancer Female, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Ductal Carcinoma in Situ, Ductal Breast Carcinoma, Lobular Breast Carcinoma
- Interventions
- Breast reconstruction decision aid, Educational website
- Other
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more
- Conditions
- Idiopathic Thrombocytopenic Purpura (ITP)
- Interventions
- E5501
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Bacterial Infection
- Interventions
- ceftaroline, linezolid, Aztreonam
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 13
- States / cities
- Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
- Conditions
- Triple Negative Breast Neoplasms, Breast Cancer
- Interventions
- Pembrolizumab, Mifepristone
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Melanoma (Skin)
- Interventions
- temsirolimus
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 18
- States / cities
- Duarte, California • Los Angeles, California • Pasadena, California + 14 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab
- Drug
- Lead sponsor
- SOLTI Breast Cancer Research Group
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 26
- States / cities
- Clearwater, Florida • Coral Gables, Florida • Hollywood, Florida + 22 more
- Conditions
- Herpes Simplex, HIV Infections, Herpes Genitalis
- Interventions
- Valacyclovir hydrochloride
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 20
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 17 more
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Invasive Breast Carcinoma, Non-Metastatic Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Boost, Therapeutic Surgical Procedure, Whole Breast Irradiation, Breast MRI
- Other · Radiation · Procedure
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 11
- States / cities
- Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 7 more
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Breast Adenocarcinoma, Inflammatory Breast Carcinoma
- Interventions
- pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Lancaster, California • South Pasadena, California
- Conditions
- Verruca Vulgaris
- Interventions
- 2014-ALC-919-US, Vehicle-Control Topical Solution
- Drug
- Lead sponsor
- Veloce BioPharma LLC
- Industry
- Eligibility
- 8 Years to 90 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Fort Washington, Pennsylvania